{"transactions":[{"id":1210318,"issuer":{"id":7935,"kind":"organization","name":"Senti Biosciences Holdings, Inc."},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-03-12T20:31:26.000Z","date":"2025-03-10","kind":"exercise","planned":false,"acquired":false,"shares":2222,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"exercise_date":"2025-03-10","underlying":"Common Stock","underlying_shares":2222000},"source":{"system":"sec-edgar","filing":"0001578563-25-000173","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856325000173/primary_doc.xml","form_type":"4"}},{"id":1210317,"issuer":{"id":7935,"kind":"organization","name":"Senti Biosciences Holdings, Inc."},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-12T20:31:26.000Z","date":"2025-03-10","kind":"exercise","planned":false,"acquired":true,"shares":2222000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":2809848,"source":{"system":"sec-edgar","filing":"0001578563-25-000173","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856325000173/primary_doc.xml","form_type":"4"}},{"id":1336212,"issuer":{"id":7935,"kind":"organization","name":"Senti Biosciences Holdings, Inc."},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-12-11T19:38:16.000Z","date":"2024-12-09","kind":"purchase","planned":false,"acquired":true,"shares":3333000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The warrant becomes exercisable once the Issuer's stockholders first approve the issuance of the Issuer's common stock underlying the warrants in excess of the limitations imposed by Rule 5635 of the Nasdaq Stock Market listing rules."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":3330000,"derivative":{"exercise_price":2.3,"expiration_date":"2029-12-09","underlying":"Common Stock","underlying_shares":3333000},"source":{"system":"sec-edgar","filing":"0001578563-24-000493","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000493/primary_doc.xml","form_type":"4"}},{"id":1336211,"issuer":{"id":7935,"kind":"organization","name":"Senti Biosciences Holdings, Inc."},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-12-11T19:38:16.000Z","date":"2024-12-09","kind":"purchase","planned":false,"acquired":true,"shares":2222,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") will convert into 1,000 shares of the Issuer's common stock upon the date that the Issuer's stockholders first approve the issuance of the Issuer's common stock upon conversion of the shares of Series A."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") will convert into 1,000 shares of the Issuer's common stock upon the date that the Issuer's stockholders first approve the issuance of the Issuer's common stock upon conversion of the shares of Series A."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") will convert into 1,000 shares of the Issuer's common stock upon the date that the Issuer's stockholders first approve the issuance of the Issuer's common stock upon conversion of the shares of Series A."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") will convert into 1,000 shares of the Issuer's common stock upon the date that the Issuer's stockholders first approve the issuance of the Issuer's common stock upon conversion of the shares of Series A."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":2222,"derivative":{"underlying":"Common Stock","underlying_shares":2222000},"source":{"system":"sec-edgar","filing":"0001578563-24-000493","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000493/primary_doc.xml","form_type":"4"}},{"id":1641383,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":890671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":509855},"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641382,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":1030086,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":589662},"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641381,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-4 Convertible Preferred Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":2062387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1180592},"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641380,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":3093580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering (\"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering (\"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering (\"IPO\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1770888},"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641379,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":509855,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":4050997,"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641378,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":589662,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":3541142,"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641377,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":1180592,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":2951480,"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641376,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":1770888,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering (\"IPO\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":1770888,"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1824314,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-07-24T17:51:04.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":1307401,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1307401},"source":{"system":"sec-edgar","filing":"0001578563-23-000065","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856323000065/primary_doc.xml","form_type":"4"}},{"id":1824313,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-24T17:51:04.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":1307401,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":1307401,"source":{"system":"sec-edgar","filing":"0001578563-23-000065","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856323000065/primary_doc.xml","form_type":"4"}},{"id":2541846,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":1,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":2,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-10-15T17:05:24.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":6076072,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":955507},"source":{"system":"sec-edgar","filing":"0001578563-21-000038","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856321000038/primary_doc.xml","form_type":"4"}},{"id":2541845,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":1,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":2,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-10-15T17:05:24.000Z","date":"2021-10-13","kind":"exercise","acquired":false,"shares":11362462,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1786831},"source":{"system":"sec-edgar","filing":"0001578563-21-000038","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856321000038/primary_doc.xml","form_type":"4"}},{"id":2541844,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":1,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":2,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2021-10-15T17:05:24.000Z","date":"2021-10-13","kind":"exercise","acquired":true,"shares":2742338,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V."}],"balance_after":2742338,"source":{"system":"sec-edgar","filing":"0001578563-21-000038","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856321000038/primary_doc.xml","form_type":"4"}},{"id":2657643,"issuer":{"id":5739,"kind":"organization","name":"Century Therapeutics, Inc.","symbol":"IPSC"},"owners":[{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":1,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":2,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-06-23T16:41:21.000Z","date":"2021-06-22","kind":"exercise","acquired":false,"shares":3862813,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1535238},"source":{"system":"sec-edgar","filing":"0001209191-21-042752","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000120919121042752/doc4.xml","form_type":"4"}},{"id":2657642,"issuer":{"id":5739,"kind":"organization","name":"Century Therapeutics, Inc.","symbol":"IPSC"},"owners":[{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":1,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":2,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-06-23T16:41:21.000Z","date":"2021-06-22","kind":"exercise","acquired":false,"shares":26143790,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10390600},"source":{"system":"sec-edgar","filing":"0001209191-21-042752","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000120919121042752/doc4.xml","form_type":"4"}},{"id":2657641,"issuer":{"id":5739,"kind":"organization","name":"Century Therapeutics, Inc.","symbol":"IPSC"},"owners":[{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":1,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":2,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-23T16:41:21.000Z","date":"2021-06-22","kind":"purchase","acquired":true,"shares":750000,"price":20,"value":15000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V."}],"balance_after":12675838,"source":{"system":"sec-edgar","filing":"0001209191-21-042752","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000120919121042752/doc4.xml","form_type":"4"}},{"id":2657640,"issuer":{"id":5739,"kind":"organization","name":"Century Therapeutics, Inc.","symbol":"IPSC"},"owners":[{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":1,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":2,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-23T16:41:21.000Z","date":"2021-06-22","kind":"exercise","acquired":true,"shares":1535238,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V."}],"balance_after":11925838,"source":{"system":"sec-edgar","filing":"0001209191-21-042752","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000120919121042752/doc4.xml","form_type":"4"}},{"id":2657639,"issuer":{"id":5739,"kind":"organization","name":"Century Therapeutics, Inc.","symbol":"IPSC"},"owners":[{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":1,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":2,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-23T16:41:21.000Z","date":"2021-06-22","kind":"exercise","acquired":true,"shares":10390600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V."}],"balance_after":10390600,"source":{"system":"sec-edgar","filing":"0001209191-21-042752","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000120919121042752/doc4.xml","form_type":"4"}},{"id":2958899,"issuer":{"id":3457,"kind":"organization","name":"Elanco Animal Health Inc","symbol":"ELAN"},"owners":[{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":1,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":2,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-03T16:55:40.000Z","date":"2020-12-03","kind":"sale","acquired":false,"shares":54500000,"price":29.8416,"value":1626367200.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to an underwriting agreement, dated November 30, 2020, and in connection with the registered public offering of shares of common stock of the Issuer (\"Common Stock\") pursuant to the prospectus, dated as of January 21, 2020 and filed with the U.S. Securities and Exchange Commission (the \"SEC\") on January 21, 2020 and the prospectus supplement dated as of November 30, 2020 and filed with the SEC on December 2, 2020, which offering settled on December 3, 2020, Bayer World Investments B.V. sold 54,500,000 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported as sold were, and those reported as held after the transaction are, held directly by Bayer World Investments B.V., which is an indirect wholly owned subsidiary of Bayer Aktiengesellschaft. Bayer Aktiengesellschaft may be deemed to beneficially own the shares of the Issuer's Common Stock beneficially owned by Bayer World Investments B.V."}],"balance_after":18446429,"source":{"system":"sec-edgar","filing":"0000899243-20-032676","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000089924320032676/doc4.xml","form_type":"4"}}]}